1Descamps -Latscha B,Witko-Sarsat V.Importance of oxidatively modified proteins in chronic renal failure.Kidney Int,2001,78:S108
2Drueke T,Witko Sarsat V,Massy ZA,et al.Iron therapy,advanced oxidation protein products,and carotid artery intima media thickness in end stage renal disease.Circulation,2002,106(17):2212
4Kalousova M,Zima T,Tesar V,et al.Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients[J].Blood Purff,2002,20:531-536
5Witko-Sarsat V,Friedllander M,Nguyen KT,et al.Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol,1998,161(5):2524
6Foley RN,Parfrey PS,Sarnak MJ.Clinical epidemiology of cardiovascular disease in chronic renal disease.AmJ Kidney Dis,1998,32[SuPP13]:l12-119
7Bostom AG,Lathrop L.HyPerhomocysteinemia in end-stage renal disease:Prevalence,etiology,and potential relationship to artherosclerotic outcomes.Kidney Int,1997,52:10-20
9Ma KW,Greene EL,Reij L.Cardiovascular risk factors in chronic renal failure and hemodialysis Populations.Am J Kid Dis,1992,19:505-513
10Descamps-Latscha-B,Jungers-P,Witko-Sarsat -V.Immune system dysregulation in uremia:Role of oxidative stress.Blood-PurifK,2002,20 (5):481 484
二级参考文献17
1[1]Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int, 1996, 49(5):1304
2[2]Witko-Sarsat V, Friedlander M, Nguyen AT et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol,1998, 161(5):2524
3[3]Witko-Sarsat V, Gausson V, Nguyen AT et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int, 2003, 64(1):82
4[4]Kaneda H, Taguchi J, Ogasawara K et al. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis, 2002, 162(1):221
5[5]Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation, 2002, 106(17):2212
6[7]Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods, 1989, 119(2):203
